• Transmission Dynamics of Carbapenemase Genes in CREC in Guan

  2026-06-18

  This study systematically investigates the prevalence, genetic context, and horizontal transferability of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae (CREC) across eight teaching hospitals in Guangdong, China, during the COVID-19 pandemic. The findings highlight the dominance of blaNDM-1 and the extensive multidrug resistance these strains exhibit, providing actionable insights for researchers addressing Gram-negative bacterial infection dynamics.

• Gamithromycin PK/PD in Bovine Respiratory Disease: PELF Pred

  2026-06-18

  This study rigorously defines how gamithromycin concentrations in pulmonary epithelial lining fluid (PELF) better predict treatment outcomes for naturally occurring bovine respiratory disease (BRD) than plasma levels. By integrating PK/PD modeling and clinical efficacy, the findings guide dose optimization strategies for combating key respiratory pathogens such as Pasteurella multocida.

• Marein Reverses ABCG2-Mediated Chemoresistance via Competiti

  2026-06-17

  This study identifies marein, a natural chalcone from Coreopsis tinctoria, as a potent and selective inhibitor of the ABCG2 drug transporter in multidrug-resistant cancer cells. By competitively blocking ABCG2, marein restores the intracellular accumulation and efficacy of chemotherapeutic agents such as doxorubicin, providing a novel strategy to overcome one of the main barriers in cancer chemotherapy.

• BAY-826: Potent Small Molecule Inhibitor for Angiogenesis Re

  2026-06-17

  BAY-826 is transforming angiopoietin-PEDF pathway dissection by enabling precise manipulation of retinal neuron survival in advanced in vitro and co-culture models. This potent small molecule inhibitor delivers both workflow clarity and troubleshooting flexibility for researchers targeting neurovascular mechanisms.

• AZ505: Precision SMYD2 Inhibition for Epigenetic Research

  2026-06-16

  AZ505, a potent and selective SMYD2 inhibitor from APExBIO, empowers researchers to dissect epigenetic regulation and disease mechanisms with high specificity. Its proven efficacy in models of cancer and renal fibrosis enables advanced experimental design, reproducible workflows, and new therapeutic insights.

• Efficient GRO-seq Protocol Enhances Nascent RNA Profiling in

  2026-06-16

  Chen et al. introduce an optimized, cost-effective GRO-seq protocol for bread wheat that integrates an rRNA depletion step, dramatically increasing usable data yield. This approach enables more accessible, high-resolution profiling of nascent transcription in complex plant genomes, with broad implications for transcriptomic research.

• Dual-Action Inhibitors Accelerate p38α MAPK Dephosphorylatio

  2026-06-15

  The referenced study reveals that specific kinase inhibitors not only block p38α MAP kinase activity but also accelerate its dephosphorylation by stabilizing a phosphatase-favored conformation. This dual-action mechanism offers new strategic insights for improving selectivity and efficacy in inflammation and apoptosis research.

• (S)-(+)-Ibuprofen: Precision COX Inhibitor for Inflammation

  2026-06-15

  (S)-(+)-Ibuprofen stands out as the pharmacologically active COX inhibitor, enabling advanced inflammation pathway research and reproducible pain mechanism studies. This article delivers actionable protocols, sustainability insights, and troubleshooting strategies for maximizing (S)-(+)-Ibuprofen’s impact in both cellular and in vivo models.

• Merimepodib (VX-497): Targeting Host Nucleotide Metabolism i

  2026-06-14

  This thought-leadership article explores how Merimepodib (VX-497), a selective oral IMPDH inhibitor, is redefining strategies for translational research in oncology, immunology, and antiviral science. Drawing on mechanistic insights and landmark studies—including recent work demonstrating its suppression of PEDV replication by targeting host nucleotide metabolism—the article provides actionable guidance for experimental design, protocol optimization, and cross-domain innovation. APExBIO’s Merimepodib is spotlighted not merely as a research reagent, but as a strategic enabler for next-generation investigations.

• DiscoveryProbe™ L1023: A Validated Anti-Cancer Compound Libr

  2026-06-13

  The DiscoveryProbe™ Anti-cancer Compound Library (SKU: L1023) is a rigorously validated resource comprising 1,164 bioactive compounds targeting key oncogenic signaling pathways. This L1023 Anti-Cancer Compound Library supports high-throughput screening of anti-cancer agents and pathway-specific drug discovery with robust, peer-reviewed evidence.

• Natural Compounds Target SARS-CoV-2 Protease and Spike: Dock

  2026-06-12

  This study identifies repurposed natural compounds, notably vitamins, as potential inhibitors of SARS-CoV-2 by targeting both the main protease (3CLpro) and the spike protein receptor-binding domain using molecular docking and dynamics simulation. The findings inform ongoing antiviral therapeutics research by highlighting accessible agents for disrupting viral entry and replication.

• Simvastatin (Zocor): Applied Workflows for Lipid and Cancer

  2026-06-12

  Simvastatin (Zocor) from APExBIO provides a multifaceted tool for dissecting cholesterol metabolism and cancer cell fate, with validated protocols for apoptosis, autophagy, and lipid regulation. This guide distills the latest workflows, practical troubleshooting, and novel assay innovations to unlock Simvastatin’s full potential in both cardiovascular and oncology research.

• L1023 Anti-Cancer Compound Library: Mechanistic Insights and

  2026-06-11

  Explore the L1023 Anti-Cancer Compound Library's unique utility for dissecting oncogenic signaling, with a special focus on mechanistic pathway analysis and real-world assay design. Gain in-depth guidance and practical insights not found in other resources.

• Tetrahydromagnolol as a Peripheral CB2 Receptor Agonist: App

  2026-06-11

  Tetrahydromagnolol offers unmatched selectivity and potency for peripheral CB2 receptor research, making it a versatile tool for modeling anti-inflammatory and analgesic mechanisms. Its dual action as a GPR55 antagonist uniquely positions it for dissecting complex GPCR signaling in both inflammation and metastatic cancer models.

• Strategic NF-κB Modulation: QNZ (EVP4593) in Translation

  2026-06-10

  Explore how QNZ (EVP4593) accelerates translational research by precisely targeting the NF-κB pathway. This article combines mechanistic insights with practical guidance for deploying this anti-inflammatory compound in neurodegenerative and inflammatory models, referencing both clinical challenges and the latest experimental advances.

15270 records 1/1018 page Next 12345 下5页 Last page